Literature DB >> 8386772

Structure determination of antiviral compound SCH 38057 complexed with human rhinovirus 14.

A Zhang1, R G Nanni, T Li, G F Arnold, D A Oren, A Jacobo-Molina, R L Williams, G Kamer, D A Rubenstein, Y Li.   

Abstract

SCH 38057 (1-[6-(2-chloro-4-methoxyphenoxy)-hexyl]imidazole hydrochloride) is a new, water-soluble antiviral compound that has inhibitory activities against a number of picornavirus infections. The structure of the human rhinovirus 14 (HRV14) complex with SCH 38057 was determined at 3.0 A resolution by single-crystal diffraction techniques using synchrotron X-radiation. SCH 38057 was found to bind at the innermost end of the hydrophobic pocket within the capsid protein VP1, a locus of binding of other antipicornaviral agents; however, the complex differs from previously reported complexes in two important aspects. It leaves a considerable volume near the entrance to the binding pocket unoccupied. In addition, the alterations in the conformation of the VP1 polypeptide are similar to, but more extensive than those observed in HRV14 complexes with other antiviral agents. Although only 9 amino acids of VP1 have close contacts with the SCH 38057 molecule (within 3.6 A), at least 36 amino acids from both VP1 and VP3 have significantly altered conformations (C alpha movement > 0.5 A versus native). The structures of complexes of HRV14 with SCH 38057 and WIN 51711 are compared. Aromatic ring interactions between picornavirus capsid residues and antiviral inhibitors are proposed to be among the major determinants for positioning of these compounds.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386772     DOI: 10.1006/jmbi.1993.1206

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  9 in total

Review 1.  Problems and prospects of developing effective therapy for common cold viruses.

Authors:  S L Johnston
Journal:  Trends Microbiol       Date:  1997-02       Impact factor: 17.079

2.  SCH 48973: a potent, broad-spectrum, antienterovirus compound.

Authors:  P J Buontempo; S Cox; J Wright-Minogue; J L DeMartino; A M Skelton; E Ferrari; R Albin; E J Rozhon; V Girijavallabhan; J F Modlin; J F O'Connell
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.

Authors:  A D Smith; S C Geisler; A A Chen; D A Resnick; B M Roy; P J Lewi; E Arnold; G F Arnold
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected].

Authors:  Mauro Lapelosa; Gail Ferstandig Arnold; Emilio Gallicchio; Eddy Arnold; Ronald M Levy
Journal:  J Mol Biol       Date:  2010-02-04       Impact factor: 5.469

5.  Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope.

Authors:  Gail Ferstandig Arnold; Paola K Velasco; Andrew K Holmes; Terri Wrin; Sheila C Geisler; Pham Phung; Yu Tian; Dawn A Resnick; Xuejun Ma; Thomas M Mariano; Christos J Petropoulos; John W Taylor; Hermann Katinger; Eddy Arnold
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

6.  Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1.

Authors:  D A Resnick; A D Smith; S C Gesiler; A Zhang; E Arnold; G F Arnold
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

7.  Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses.

Authors:  Guohua Yi; Mauro Lapelosa; Rachel Bradley; Thomas M Mariano; Denise Elsasser Dietz; Scott Hughes; Terri Wrin; Chris Petropoulos; Emilio Gallicchio; Ronald M Levy; Eddy Arnold; Gail Ferstandig Arnold
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

Review 8.  Picornavirus inhibitors.

Authors:  L Carrasco
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

Review 9.  Rhinovirus Inhibitors: Including a New Target, the Viral RNA.

Authors:  Antonio Real-Hohn; Dieter Blaas
Journal:  Viruses       Date:  2021-09-07       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.